Company Overview
Management
Board of Directors
Partners
Investors
AEROSPAN
NASACORT HFA
Press Releases
RECENT NEWS
ACTON PHARMACEUTICALS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR AEROSPAN® (flunisolide HFA, 80 mcg) INHALATION AEROSOL FOR ASTHMA
ACTON PHARMACEUTICALS, INC. ANNOUNCES LICENSE AGREEMENT WITH SANOFI U.S. FOR NASACORT HFA (triamcinolone acetonide) NASAL AEROSOL
ACTON PHARMACEUTICALS, INC. ANNOUNCES PUBLICATION OF AEROSPAN (flunisolide HFA) PEDIATRIC LINEAR GROWTH STUDY IN ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY
ACTON PHARMACEUTICALS, INC. ANNOUNCES ADDITIONS TO THE EXECUTIVE MANAGEMENT TEAM
ACTON PHARMACEUTICALS, INC. SUBMITS NDA SUPPLEMENT TO FDA FOR AEROSPAN (flunisolide HFA, 80 mcg) INHALATION AEROSOL
Welcome to Acton Pharmaceuticals
Acton Pharmaceuticals is a specialty respiratory company focused on the acquisition, development and commercialization of products to treat pulmonary diseases.
